Philadelphia skyline; Photo by Ed Yakovich

The AACR conference Hematologic Malignancies: Translating Discoveries to Novel Therapies took place September 20-23, 2014, in Philadelphia, Pennsylvania.

Targeting drug resistance earlier

Print Friendly, PDF & Email


drug_release_in_cancer_cell_credit_PNAS.jpg
Drug release in a cancer cell
Credit: PNAS

A combination treatment strategy that takes tumor evolution into account could help us avoid drug resistance in hematologic malignancies, researchers say. Preclinical experiments suggest we can prevent resistance by starting secondary treatment prior to relapse. For example, a patient receiving dasatinib for acute lymphoblastic leukemia (ALL)... [Read Article]

Print Friendly, PDF & Email

Drug could treat a range of blood cancers

Print Friendly, PDF & Email


multiple_myeloma_240.jpg
Multiple myeloma

A drug that targets the ribosome may be active in a broad range of hematologic malignancies, researchers say. The drug, CX-5461, inhibits the protein RNA polymerase I (Pol I), which is consistently upregulated in hematologic and other cancers. CX-5461 significantly prolonged survival in mouse models of refractory acute myeloid leukemia (AML) and multiple... [Read Article]

Print Friendly, PDF & Email

Method can detect drivers of AML

Print Friendly, PDF & Email


AML_in_bone_marrow.jpg
AML in the bone marrow

Super-enhancer profiling can unearth biomarkers and therapeutic targets for acute myeloid leukemia (AML), according to research presented at the AACR conference Hematologic Malignancies: Translating Discoveries to Novel Therapies. Researchers used high-throughput ChIP sequencing to identify super-enhancer domains in a cohort of AML patients. And this revealed both known and previously... [Read Article]

Print Friendly, PDF & Email

Murine studies support use of TKIs in ALL subtype

Print Friendly, PDF & Email


lab_mouse_240.jpg
Lab mouse

Experiments in mice reinforce the idea that tyrosine kinase inhibitors (TKIs) can treat patients with Ph-like acute lymphoblastic leukemia (ALL). Investigators recently identified genomic alterations in Ph-like ALL that suggest these patients might respond to TKIs, and tests in a small number of patients supported this theory. Now, preclinical results show that kinase... [Read Article]

Print Friendly, PDF & Email

ETBs prove effective against lymphoma and myeloma

Print Friendly, PDF & Email


researchers_microscope_NCI_Rhoda_Baer_230.jpg
Researchers in the lab
Credit: Rhoda Baer

A pair of engineered toxin bodies (ETBs) can successfully treat Burkitt lymphoma and multiple myeloma, according to preclinical research presented at the AACR conference Hematologic Malignancies: Translating Discoveries to Novel Therapies. The ETBs, known as MT-4007 and MT-4007-D, work by targeting CD38. They greatly reduced tumor burden... [Read Article]

Print Friendly, PDF & Email

Drugs demonstrate inconsistent synergy in CLL, MCL

Print Friendly, PDF & Email


mantle_cell_lymphoma_micrograph_showing_wiki_240.jpg
Mantle cell lymphoma

The Bcl-2 inhibitor ABT-199 and the Bruton tyrosine kinase inhibitor ibrutinib can have a synergistic effect against mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), preclinical data suggest. In one set of experiments with MCL and CLL samples, the drugs induced apoptosis at a much higher rate when used together than... [Read Article]

Print Friendly, PDF & Email